Iovance Adds Precision TIL Strategy as Enriched Lung Subgroup Hits 59.1% ORR
IOVA has more than doubled off its 52-week low of $1.76 on elevated volume (3.5× avg).
Summary
Iovance's updated IOV-LUN-202 data show a 24.6% response rate overall but 59.1% in a biomarker-enriched subgroup, prompting a new registrational-intent POSITILITY cohort enrolling November 2026 and a planned 2027 sBLA.
Key Events · Product Development and Regulatory · IOVA
-
Enriched Subgroup Reaches 59.1% ORR
In 22 patients with KRAS wild-type, HER2 wild-type tumors and current or former smoking history, 13 responded (59.1%), including both complete responses; the broader 69-patient non-squamous population showed 24.6% (17/69).
-
KRAS Status Splits Response Sharply
KRAS wild-type patients responded at 43.3% (13/30) versus 11.4% (4/35) in KRAS-mutant disease, the basis for the precision TIL strategy.
-
POSITILITY Cohort Enrolling November 2026
A first-in-class, prospective biomarker-enriched cohort with registrational intent starts enrollment in November 2026 at the first of over 70 existing IOV-LUN-202 sites, subject to FDA feedback.
-
2027 sBLA Planned for Broader Population
Cohorts 1 and 2 are completing enrollment with roughly 80 non-squamous NSCLC patients expected in the final dataset; an sBLA in non-squamous mNSCLC is planned for 2027, with FDA discussions ongoing.
Analysis · IOVA · Life Sciences
The headline 24.6% response rate in 69 non-squamous NSCLC patients is unchanged in substance from prior reports, so the broad second-line program is not the news. What matters is the biomarker split: KRAS wild-type patients responded at 43.3% versus 11.4% in KRAS-mutant disease, and layering HER2 wild-type status and smoking history lifts the enriched group to 59.1% (13 of 22), with both complete responses falling inside it. That gives Iovance a defensible path to a narrower, higher-response registrational study — POSITILITY begins enrolling in November 2026 — rather than a broad sBLA on a mid-20s response rate. The trade-off is a smaller addressable population, though management sizes the enriched group at roughly 45% of U.S. non-squamous mNSCLC cases. The planned 2027 sBLA for the broader population still depends on ongoing FDA discussions, and the subgroup analysis is retrospective, so confirmation in the prospective cohort is the real test.
How filings like this one have moved
In the 30 days to Oct 29, 2026, 30.9% of the 1649 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.02%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IOVA was trading at $9.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.3B. The 52-week trading range was $1.76 to $15.37. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.